National Vision price to free cash flow EYE
Market value divided by free cash flow over the last twelve months, since 2018.
- Today, Nov 2, 2026
- 27.6×
- 8-year median
- 31.3×
- Against its 8-year history
- 40th
- percentile: 0 is its lowest day, 100 its highest
- 8-year range
- 11.7× to 494×
- Peer median
- 16.9×
National Vision's price to free cash flow is 27.6× as of Nov 2, 2026.
That is below its 8-year median of 31.3×, close to the middle of its last 8 years.
Over that time it ranged from 11.7× in Jun 2026 to 494× in Dec 2018.
The median for 10 medical instruments and supplies stocks of a similar size is 16.9×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 27.6× | 11.7× | 31.1× |
| 2025 | 26.8× | 22.7× | 42.9× |
| 2024 | 31.0× | 21.1× | 78.0× |
| 2023 | 39.2× | 34.5× | 313× |
| 2022 | 129× | 17.7× | 136× |
| 2021 | 23.3× | 16.8× | 31.5× |
| 2020 | 27.8× | 17.7× | 82.2× |
| 2019 | 44.0× | 36.7× | 492× |
| 2018 | 442× | 403× | 494× |
Against its peers
Companies in Medical - Instruments & Supplies nearest National Vision's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| EYENational Vision | 27.6× |
| CDRECadre | 17.3× |
| STAAStaar Surgical | n/m |
| BVSBioventus | 11.7× |
| IARTIntegra Lifesciences | 12.3× |
| IRMDIradimed | 38.9× |
| LMATLemaitre Vascular | 25.2× |
| INSPInspire Medical Systems | 16.6× |
| UFPTUFP Technologies | n/m |
| MOVMovado | 10.0× |
| WRBYWarby Parker | 136× |
| Peer median | 16.9× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on National Vision
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.